Is Retatrutide affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: GIPR, GLP1R

Retatrutide is affected by pharmacogenetics through the GIPR and GLP1R genes. Your genotype for these genes can change how your body processes Retatrutide, which can affect both how well it works and how well you tolerate it. The strongest evidence level on this page is Moderate, based on CPIC or FDA guidelines.

What's in Retatrutide

retatrutide affected by GIPR, GLP1R

Affected by GIPR, GLP1R · Gene2Rx · Moderate evidence

Read the full retatrutide genetics guide →

Retatrutide phenotype recommendations

Published guidance from Gene2Rx on how retatrutide should be dosed or substituted based on your GLP1R, GIPR phenotype.

Phenotype	What it means	Recommendation	Evidence
Typical Response GLP1R	Your genotype suggests a typical response to retatrutide with average efficacy and side-effect risk.	Gene2Rx Standard dosing and titration are expected to produce an average response.	Moderate
Enhanced Response (heterozygous) GLP1R	You may lose slightly more weight on retatrutide than average, with a modestly higher chance of nausea or vomiting.	Gene2Rx Use standard dosing. Counsel on the likelihood of somewhat greater weight loss and slightly higher GI side-effect risk; consider slower titration if early side effects emerge.	Moderate
Enhanced Response (homozygous) GLP1R	You are likely to lose more weight on retatrutide than average, but you also have a higher chance of nausea or vomiting.	Gene2Rx Use standard dosing. Counsel on the likelihood of greater weight loss and higher GI side-effect risk; consider a slower titration schedule to mitigate side effects.	Moderate
Indeterminate GLP1R	We were not able to determine your GLP1R genotype, so we cannot personalize guidance for retatrutide.	Gene2Rx Use standard dosing and titration. Monitor response.	—
Not available GLP1R	We do not have a GLP1R result for you, so we cannot personalize guidance for retatrutide.	Gene2Rx Use standard dosing and titration. Monitor response.	—
Normal Function GIPR	Your GIPR genotype suggests typical tolerability of retatrutide.	Gene2Rx Standard dosing and titration. No specific precautions based on GIPR genotype.	Moderate
Decreased Function GIPR	You have a somewhat higher chance of nausea or vomiting on retatrutide. If side effects become a problem, semaglutide is not affected by this variant.	Gene2Rx Consider a slower dose-escalation schedule for retatrutide. If side effects are intolerable, a GLP1R-only agonist such as semaglutide is unaffected by this variant and may be an alternative.	Moderate
Poor Function GIPR	You have a notably higher chance of nausea or vomiting on retatrutide. Semaglutide is not affected by this variant and may be better tolerated.	Gene2Rx Consider slower dose escalation for retatrutide, or consider a GLP1R-only agonist such as semaglutide as an alternative (unaffected by this variant).	Moderate
Indeterminate GIPR	We were not able to determine your GIPR genotype, so we cannot personalize GI side-effect guidance for retatrutide.	Gene2Rx Use standard dosing and titration for retatrutide. Monitor for GI side effects.	—
Not available GIPR	We do not have a GIPR result for you, so we cannot personalize GI side-effect guidance for retatrutide.	Gene2Rx Use standard dosing and titration for retatrutide. Monitor for GI side effects.	—

Source: Gene2Rx

The genes behind the guidance

GIPR Gastric Inhibitory Polypeptide Receptor

GIPR is the receptor for GIP, the second incretin hormone. It is the target of the GIP arm of tirzepatide and retatrutide. The Glu354Gln variant (rs1800437) lowers GIPR function, and carriers are more likely to get moderate-to-severe nausea and vomiting on GIP-active drugs. The variant doesn't matter for GLP-1-only drugs like semaglutide.

If someone is struggling with nausea on tirzepatide and carries the Gln354 variant, switching to a GLP-1-only drug often fixes it, since GIPR isn't part of the picture for those drugs.

See all drugs affected by GIPR →

GLP1R Glucagon-Like Peptide-1 Receptor

GLP1R is the cell-surface receptor that GLP-1 drugs like semaglutide and tirzepatide bind to. A common variant (rs10305420, Pro7Leu) changes how efficiently the receptor gets made and shipped to the cell surface. Leu7 carriers tend to lose a bit more weight on GLP-1 drugs, but they also get more nausea and vomiting.

Roughly a third of people of European descent carry at least one Leu7 allele. The variant doesn't decide whether a GLP-1 drug will work for someone. It changes how strong the response is and shifts the side-effect profile.

See all drugs affected by GLP1R →

Browse the full drug-class: Weight management (GLP-1 agonists).

Find out how your genetics affect Retatrutide

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.